EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse: Prevalence, Predictors, and Association With Outcomes

Yan Topilsky iD, Benjamin Essayagh iD, Giovanni Benfari iD, Thierry Le Tourneau iD, Clemence Antoine, Francesco Grigioni iD, Jean-Christian Roussel iD, Jeroen J Bax iD, Nina Ajmone Marsan iD, Aniek van Wijngaarden iD, Christophe Tribouilloy iD, Itamar Loewenstein und 4 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.040868 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Yan Topilsky und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Tel Aviv Medical Center and Sackler Faculty of Medicine Tel Aviv Israel. Hauptthemen laut MEDLINE: Hypertrophy, Left Ventricular, Mitral Valve Insufficiency, Mitral Valve Prolapse, Ventricular Function, Left. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Left ventricular (LV) end‐systolic enlargement in severe degenerative mitral‐regurgitation (MR) is a class I surgical trigger. Whether it occurs disproportionately to less‐than‐severe MR due to mitral valve prolapse and is associated with mortality are unknown. We aimed to analyze prevalence and association with survival of disproportionate LV enlargement in less‐than‐severe MR.

Methods

A multicenter cohort international study enrolled 2848 consecutive patients (52% women, 69±16 years) with degenerative MR prospectively quantified and graded mild or moderate. Primary end point was survival under medical management. Secondary outcome was survival throughout follow‐up stratified by performance of early mitral surgery within 3 months postdiagnosis.

Results

Among LV remodeling parameters (abnormal end‐diastolic diameter, LV end‐systolic diameter [LVESD] absolute and indexed), LVESD ≥40 mm (present in 12.4%) was the sole independent associate of reduced survival (5‐year 70±3 versus 76±9%; P =0.009). LVESD ≥40 mm was independently linked to larger body surface area, effective regurgitant orifice, and left atrium, and to male sex and diabetes. With multivariable comprehensive adjustment, LVESD ≥40 mm (adjusted hazard ratio [aHR], 1.25 [95% CI, 1.005–1.53]; P =0.04) remained associated with excess mortality under medical management, even after adjustment for lowered ejection fraction (aHR, 1.49 [95% CI, 1.13–1.95]; P =0.004) and in all patient subsets. Among patients with moderate degenerative MR and LVESD ≥40 mm, 22% underwent mitral surgery within 3 months, which was associated with superior survival, even after comprehensive adjustment (aHR, 0.11 [95% CI, 0.005–0.51]; P =0.002).

Conclusions

Disproportionate LV enlargement in patients with less‐than‐severe degenerative MR is common, particularly with larger bodies, regurgitation, and overall cardiac remodeling. LVESD ≥40 mm is associated with worse survival independent of all baseline characteristics, even lowered ejection fraction, and represents a marker for risk stratification of patients who are generally not yet considered for medical or surgical/interventional treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertrophy, Left VentricularMitral Valve InsufficiencyMitral Valve ProlapseVentricular Function, LeftVentricular RemodelingAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrevalenceProspective StudiesRisk FactorsSeverity of Illness IndexTime Factors

Stichwörter der Autor:innen

degenerative mitral regurgitationleft ventricularmitral valve prolapse

Autor:innen und Institutionen

  • Department of Cardiology Tel Aviv Medical Center and Sackler Faculty of Medicine Tel Aviv Israel.
  • Division of Cardiovascular Diseases Mayo Clinic Rochester MN USA.
  • Department of Echocardiography Cardio X Clinic Cannes France.
  • Department of Cardiology University of Nantes Nantes France.
  • Department of Cardiology University Campus Bio-Medico Rome Italy.
  • Department of Cardiology Leiden University Medical Center Leiden Netherlands.

ORCID-Profile: Yan Topilsky, Benjamin Essayagh, Giovanni Benfari, Thierry Le Tourneau, Francesco Grigioni, Jean-Christian Roussel, Jeroen J Bax, Nina Ajmone Marsan, Aniek van Wijngaarden, Christophe Tribouilloy, Aviram Hochstadt, Prabin Thapa, Hector I Michelena, Maurice Enriquez-Sarano

Zitieren

APA

Topilsky, Y., Essayagh, B., Benfari, G., Le Tourneau, T., Antoine, C., Grigioni, F., Roussel, J. C., Bax, J. J., Marsan, N. A., van Wijngaarden, A., Tribouilloy, C., Loewenstein, I., Hochstadt, A., Thapa, P., Michelena, H. I., & Enriquez-Sarano, M. (2025). Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse: Prevalence, Predictors, and Association With Outcomes. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040868

Vancouver

Topilsky Y, Essayagh B, Benfari G, Le Tourneau T, Antoine C, Grigioni F, et al. Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse: Prevalence, Predictors, and Association With Outcomes. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040868

BibTeX
@article{Topilsky2025,
  author = {Topilsky, Yan and Essayagh, Benjamin and Benfari, Giovanni and Le Tourneau, Thierry and Antoine, Clemence and Grigioni, Francesco and Roussel, Jean-Christian and Bax, Jeroen J and Marsan, Nina Ajmone and van Wijngaarden, Aniek and Tribouilloy, Christophe and Loewenstein, Itamar and Hochstadt, Aviram and Thapa, Prabin and Michelena, Hector I and Enriquez-Sarano, Maurice},
  title = {Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse: Prevalence, Predictors, and Association With Outcomes},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.040868}
}
Kostenlos starten →